Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 10/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25238614 | 0.88 | NOTUM (0.42) | NPY5RACLYNOTUMLMNA | |
| SCHEMBL26969782 | 0.87 | NOTUM (0.41) | NPY5RACLYNOTUMLMNA | |
| SCHEMBL26969758 | 0.87 | NPY5R (0.38) | NPY5RACLYNOTUMNPY2RSMN1; SMN2 | |
| SCHEMBL26969745 | 0.85 | HDAC1 (0.41) | NPY5RACLY | |
| SCHEMBL25279584 | 0.85 | ACLY (0.53) | NPY5RACLYNOTUMLMNA | |
| SCHEMBL26969707 | 0.82 | TSHR (0.38) | NPY5RACLY | |
| SCHEMBL26969727 | 0.81 | NPY5R (0.42) | NPY5RNOTUMMEN1KMT2AKDM4E | |
| SCHEMBL26969695 | 0.81 | HDAC1 (0.48) | NPY5R | |
| SCHEMBL25276070 | 0.81 | ACLY (0.46) | NPY5RACLYMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26969751 | 0.80 | ACLY (0.40) | NPY5RACLYSLC18A3SIGMAR1NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4192957-A2 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116113698-A | TRPML modulators | 卡斯玛治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2022032073-A2 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | NPY5R 681/4885ACLY 3265/4885NOTUM 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.